Track Aptinyx Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Aptinyx Inc. APTX · Stock Open Aptinyx Inc. in new tab

0.0960 USD
Add to portfolio
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...

DCF Valuation

Tweak assumptions to recompute fair value for Aptinyx Inc. (APTX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Aptinyx Inc. Logo Aptinyx Inc. Analysis (APTX)

United States Health Care Official Website Stock

Is Aptinyx Inc. a good investment? Aptinyx Inc. (APTX) is currently trading at 0.0960 USD.

Investor FAQ

Does Aptinyx Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Aptinyx Inc.?

Aptinyx Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Exchange Ticker
NMS (United States) APTX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion